Work

Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine

Year: 2025

Type: article

Abstract: T cells and reduced fibroblasts in the tumor microenvironment, as well as increasing the toxicity of the lymphocytes to the tumor cells with upregulated blood levels of INF-γ and TNF-α. Collectively, P12+GEM decreased the tumor weight and prolonged the survival of tumor-bearing mice significantly. In conclusion, P12 is a potent and selective CXCR4 antagonist that effectively enhances anti-tumor immune responses and overcomes the gemcitabine resistance of pancreatic cancer.

Source: RSC Medicinal Chemistry

DOI: 10.1039/d5md00488h

Authors: Xin Huang, Hang Wu, Ke Zhu, Xuanxin Liu, Dapeng Li, Yuanhao Liu, Tao Wang, Tao Wen, Xiaocui Fang, Jian Liu, Yanlian Yang, Jie Meng, Chen Wang, Haiyan Xu

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, National Center for Nanoscience and Technology, University of Chinese Academy of Sciences

Language: English

Topic: Chemokine receptors and signaling

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Chinese Academy of Sciences, Chinese Academy of Medical Sciences, National Key Research and Development Program of China

Awards: G4072387575, G4407716265, G7518963692

OpenAlex ID: W4412885767

FWCI: 0.373

Cites: 40

Cited by: 1

Related to: 10